ThinkGenetic, Inc., makers of an artificial intelligence-driven SymptomMatcher™ for genetic disorders, today announced the successful close of its angel round of funding for $1.5M.
by Ruth O'Keefe
ThinkGenetic, Inc., makers of an artificial intelligence-driven SymptomMatcher™ for genetic disorders, today announced the successful close of its angel round of funding for $1.5M.
Together let’s systematically accelerate detecting at-risk individuals.
ThinkGenetic does not provide medical advice, diagnosis or treatment. Click here for more information.